Exercise effects on lean body mass, muscle strength and physical function in patients with metastatic breast cancer * ACI

Eva M. Zopf ^{1,2}, Gustav Joernaker*^{3,4}, Dorothea Clauss*^{6,7}, Mark Trevaskis¹, Anouk E. Hiensch⁸, Martina E. Schmidt⁷, Evelyn M. Monninkhof⁸, Philipp Zimmer⁹, Jon Belloso¹⁰, Elisa Heyrman^{3,4}, Rodrigo Fernandez Gonzalo^{3,4}, Joachim Wiskemann¹¹, Jana Müller¹¹, Kate A. Bolam^{12,13,14,15}, Maciej Gorecki¹⁶, Renske Altena¹⁷, Christine Muttiah², Gary Richardson², Elsken van der Wall⁸, Neil K. Aaronson¹⁸, Elzbieta Senkus^{19,20}, Ander Urruticoechea¹⁰, Martijn M. Stuiver¹⁸, Karen Steindorf⁷, Wilhelm Bloch⁶, Yvonne Wengstrom⁵, Anne M. May*^{8,18}, Helene Rundqvist*^{3,4}

¹Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, ²Department of Laboratory Medicine, Division of Clinical Physiology, Karolinska Institutet, Stockholm, Sweden, ⁴Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden, 5Department of Care Science and Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden, 6Institute for Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Cologne, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany, 8University, Utrecht, U Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain, 11 Working Group Exercise Oncology, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, National Center for Tumor Diseases $Heidelberg,\ a\ partnership\ between\ DKFZ\ and\ University\ Medical\ Center\ Heidelberg,\ Heidelberg,\ Heidelberg,\ The\ Baker\ Heart\ and\ Diabetes\ Institute,\ Melbourne,\ ^{13}Department\ of\ Physical\ Activity\ and\ Health,\ The$ Swedish School of Sport and Health Sciences, Stockholm, Sweden, 14Department of Cardiometabolic Health, University of the Sunshine Coast, Sunshine Coast, Sunshine Coast, Poland Cancer Centre, Poznan, Poland, 17 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, 18 Netherlands Cancer Institute, Amsterdam, The Netherlands, 19 Medical University of Gdańsk, Gdańsk, Poland, 20 Breast Unit, University Clinical Center, Gdańsk, Poland

PROBLEM

performance associated with increased treatment-related toxicity and poorer treatment outcomes in patients with cancer. Exercise can mitigate poor skeletal muscle-related outcomes during cancer treatment, however evidence in patients with metastatic breast cancer (mBC) is lacking.

A secondary aim of the PREFERABLE -EFFECT study was to investigate the effects of a structured exercise program on body composition, muscle strength and functional performance in patients with mBC.

METHODS

Study design: multinational RCT (Fig 1).

Study population: patients with mBC, life expectancy ≥ 6 months, ECOG ≤ 2, without unstable bone metastases.

Outcome measurements at baseline, 3- and 6-months: Regional and whole body lean mass and fat mass (DXA, n=66), muscle strength (handgrip strength and hypothetical 1-repetition maximum leg strength, n=126), functional performance (5-times sit-to-stand test and Short-form Fullerton Advanced Balance scale, SF-FAB).

RESULTS


Exercise increased whole body lean mass months (effect appendicular skeletal muscle mass at 3 months (effect size=0.19) and 6 months (effect size=0.15) compared to control.

Exercise increased lower body strength at 3 and 6 months compared to control.

Exercise improved functional performance, including balance, compared to control.

No significant between-group differences were observed for handgrip strength and fat mass.

Exercise effects on lean body mass, muscle strength and functional performance




Significant between-


Control Group

Changes from baseline to 3 and 6 months were compared between groups using adjusted linear mixed models for repeated measures.


Whole body lean mass Baseline 3 months 6 months




Outcome		Mean between-group difference (95% CI)	Effect Size
Hypothetical 1-RM (kg)	3 months	18.32 (7.58, 29.06) **	0.44
	6 months	34.22 (23.00, 45.45) **	0.83
5-times Sit-to-Stand (s)	3 months	-0.52 (-1.10, 0.06)	0.14
	6 months	-0.52 (-1.10, 0.00) -1.53 (-2.11, -0.94) **	0.41
SF-FAB	3 months	0.44 (0.12, 0.76) ** Exercise	0.19
	6 months	0.44 (0.12, 0.76) *** 0.74 (0.41, 1.1) **	0.31



SUMMARY









Functional



performance

CONCLUSION

This large multinational study demonstrates that supervised exercise improves lean body muscle strength and physical mass, performance in patients with mBC. There is growing recognition that lean body mass plays a pivotal role in treatment tolerance, prognosis and overall health in patients with cancer. Based on these findings, supervised aerobic and resistance exercise should be recommended to patients with mBC.

Figure 1. Design of the PREFERABLE-EFFECT study.

INTERNATIONAL PARTNERS

metastatic

breast cancer



OPPOSITE



HEIDELBERG

NUROGAMES

UNIVERSITY HOSPITAL











ACKNOWLEDGEMENTS

This study received funding from the European Union's Horizon 2020 research and innovation program (No 825677) and the National Health and Medical Research Council of Australia (2018/GNT1170698). **H2020preferable.eu**







In Australia, participants were recruited from:





